NAB2 is a novel and highly potent small molecule that was shown to strongly and selectively protect diverse cell types from α-synuclein toxicity. NAB2 was identified by an unbiased phenotypic screening. Three chemical genetic screens in wild-type yeast cells established that NAB2 promoted endosomal transport events dependent on the E3 ubiquitin ligase Rsp5/Nedd4. These same steps were perturbed by α-synuclein itself. NAB2 reduced protein nitration in the yeast synucleinopathy model and decreased NO levels in A53T patient neurons. Moreover, NAB2 reduced the accumulation of immature ER forms of CPY in yeast. It increased the post-ER forms, and decreased the immature forms, of Nicastrin and GCase in PD patient neurons. NAB2 could be a useful chemical probe to study a druggable node in the biology of α-synuclein that can correct multiple aspects of its underlying pathology, including dysfunctional endosomal and endoplasmic reticulum-to-Golgi vesicle trafficking.

How to Use:

• In vitro:  NAB2 was used at 2.5-5 µM final concentration in vitro and in cellular assays.
• In vivo:  n/a 

Reference:

• 1. Tardiff DF, et al. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. (2013) Science. 342(6161):979-83.
• 2. Chung CY, et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. (2013) Science. 342(6161):983-7. 

Products are for research use only. Not for human use.